| Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease G Bianchini, JM Balko, IA Mayer, ME Sanders, L Gianni Nature reviews Clinical oncology 13 (11), 674-690, 2016 | 2470 | 2016 |
| Treatment landscape of triple-negative breast cancer—expanded options, evolving needs G Bianchini, C De Angelis, L Licata, L Gianni Nature reviews Clinical oncology 19 (2), 91-113, 2022 | 606 | 2022 |
| Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label … SA Hurvitz, R Hegg, WP Chung, SA Im, W Jacot, V Ganju, JWY Chiu, B Xu, ... The Lancet 401 (10371), 105-117, 2023 | 296 | 2023 |
| The immune system and response to HER2-targeted treatment in breast cancer G Bianchini, L Gianni The Lancet Oncology 15 (2), e58-e68, 2014 | 293 | 2014 |
| Immunological differences between primary and metastatic breast cancer B Szekely, V Bossuyt, X Li, VB Wali, GA Patwardhan, C Frederick, A Silber, ... Annals of Oncology 29 (11), 2232-2239, 2018 | 286 | 2018 |
| Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP … L Gianni, CS Huang, D Egle, B Bermejo, C Zamagni, M Thill, A Anton, ... Annals of Oncology 33 (5), 534-543, 2022 | 275 | 2022 |
| Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer T Iwamoto, G Bianchini, D Booser, Y Qi, C Coutant, C Ya-Hui Shiang, ... Journal of the National Cancer Institute 103 (3), 264-272, 2011 | 256 | 2011 |
| based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study A Prat, G Bianchini, M Thomas, A Belousov, MCU Cheang, A Koehler, ... Clinical Cancer Research 20 (2), 511-521, 2014 | 248 | 2014 |
| Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor–positive and–negative cancers G Bianchini, Y Qi, RH Alvarez, T Iwamoto, C Coutant, NK Ibrahim, ... Journal of Clinical Oncology 28 (28), 4316-4323, 2010 | 223 | 2010 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 198 | 2022 |
| Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation K Liang, FJ Esteva, C Albarracin, K Stemke-Hale, Y Lu, G Bianchini, ... Cancer cell 18 (5), 423-435, 2010 | 172 | 2010 |
| New strategies in breast cancer: immunotherapy L Pusztai, T Karn, A Safonov, MM Abu-Khalaf, G Bianchini Clinical Cancer Research 22 (9), 2105-2110, 2016 | 153 | 2016 |
| DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes L Santarpia, T Iwamoto, A Di Leo, N Hayashi, G Bottai, M Stampfer, ... The oncologist 18 (10), 1063-1073, 2013 | 153 | 2013 |
| Association between genomic metrics and immune infiltration in triple-negative breast cancer T Karn, T Jiang, C Hatzis, N Sänger, A El-Balat, A Rody, U Holtrich, ... JAMA oncology 3 (12), 1707-1711, 2017 | 151 | 2017 |
| Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating treatment with … L Gianni, M Mansutti, A Anton, L Calvo, G Bisagni, B Bermejo, ... JAMA oncology 4 (3), 302-308, 2018 | 148 | 2018 |
| Comparison of tumor‐infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients R Ogiya, N Niikura, N Kumaki, G Bianchini, S Kitano, T Iwamoto, ... Cancer science 107 (12), 1730-1735, 2016 | 141 | 2016 |
| Immune gene expression is associated with genomic aberrations in breast cancer A Safonov, T Jiang, G Bianchini, B Győrffy, T Karn, C Hatzis, L Pusztai Cancer research 77 (12), 3317-3324, 2017 | 135 | 2017 |
| Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial G Bianchini, L Pusztai, T Pienkowski, YH Im, GV Bianchi, LM Tseng, ... Annals of Oncology 26 (12), 2429-2436, 2015 | 135 | 2015 |
| Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre … F André, YH Park, SB Kim, T Takano, SA Im, G Borges, JP Lima, S Aksoy, ... The Lancet 401 (10390), 1773-1785, 2023 | 122 | 2023 |
| Synthetic lethal approaches exploiting DNA damage in aggressive myeloma F Cottini, T Hideshima, R Suzuki, YT Tai, G Bianchini, PG Richardson, ... Cancer discovery 5 (9), 972-987, 2015 | 118 | 2015 |
